partial AUCs for locally acting MR [Design Issues]

posted by jag009  – NJ, 2020-12-05 09:01 (1316 d 16:55 ago) – Posting: # 22116
Views: 2,885

Hi,

❝ I’m involved in the development of a MR generic drug that is locally acting in the GI tract. Despite the very helpful new EMA guideline (Guideline on equivalence studies for the demonstration of therapeutic equivalence for locally applied, locally acting products in the gastrointestinal tract, CPMP/EWP/239/95 Rev. 1, Corr.1*) I´m struggling with designing the BE studies to support submission in EU.


❝ Most problematic is the justification of the cut-off for the required partial AUCs.


Something like this in US for mesalamine ER?

https://www.accessdata.fda.gov/drugsatfda_docs/psg/PSG_022301.pdf

J

Complete thread:

UA Flag
Activity
 Admin contact
23,099 posts in 4,857 threads, 1,646 registered users;
127 visitors (0 registered, 127 guests [including 11 identified bots]).
Forum time: 02:57 CEST (Europe/Vienna)

Genius is one per cent inspiration and ninety-nine per cent perspiration.
Accordingly, a ‘genius’ is often merely a talented person
who has done all of his or her homework.    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5